Gannet BioChem Appoints Nicholas Shackley as CEO

• Gannet BioChem has appointed Nicholas Shackley as CEO and Chris Edwards as CFO following its acquisition by Ampersand Capital Partners.

Gannet BioChem, a specialty chemical Contract Development and Manufacturing Organization (CDMO), has announced key leadership appointments following its acquisition by Ampersand Capital Partners. Nicholas Shackley has been named Chief Executive Officer (CEO), while Chris Edwards joins as Chief Financial Officer (CFO). Dr. Tony Sander, a longtime company leader, has been promoted to Chief Operating Officer (COO).

Shackley brings over 25 years of experience in pharmaceuticals and chemical manufacturing. Previously, he served as Senior Vice President and Chief Commercial Officer at Lupin Manufacturing Solutions and has held executive roles at Veranova, BASF, Cambrex, and Aceto Corporation. His expertise in global business strategy and operational efficiency will be instrumental in leading Gannet BioChem through its next phase of growth. Edwards, the new CFO, has a background in global finance operations, having previously worked at Solesis, Syneos Health, Convatec, and Bristol-Myers Squibb. Meanwhile, Sander, who has been with the company since 2003, will continue to oversee manufacturing and site operations at the Huntsville, Alabama facility.

“These leadership appointments mark an exciting new chapter for Gannet BioChem as an independent company,” said Melanie Fan, Principal at Ampersand Capital Partners. “We are thrilled to welcome Nick and Chris to the leadership team, while continuing to collaborate with Tony in his expanded role.”

The new leadership team aims to drive innovation and commercial growth while reinforcing the company’s commitment to supporting biopharmaceutical and therapeutic product development.